Differential time course of the vasodilator action of various calcium antagonists

Fundamental and Clinical Pharmacology

Volumn 12, Issue 6, 1998, Pages 607-612

  Van Der Lee, R ^a   Kam, K L ^b   Pfaffendorf, M ^a   Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Calcium antagonists; Dihydropyridines; Microvessels; Pharmacokinetics

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; LACIDIPINE; LERCANIDIPINE; MEPIRODIPINE; MIBEFRADIL; NIFEDIPINE; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HEART MUSCLE; LIPOPHILICITY; MALE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT; TACHYCARDIA; VASODILATATION;

EID: 0032299957     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00993.x     Document Type: Article

References (19)

1. Ambrosioni E, Circo A. Activity of lercanidipine administered in single and repeated doses once daily as monitored over 24 h in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1997 ; 29 (suppl 2): S16-20
2. Burges R, Moisey D. Unique pharmacologic properties of amlodipine. Am J Cardiol 1994 ; 73: 2-9A
3. Göthert M, Molderings GJ. Mibefradil-and T-conotoxin GVIA-induced inhibition of noradrenaline release from the sympathetic nerves of the human heart. Naun Schmied Arch Parmacol 1997 ; 356: 860-3
4. Herbette LG et al. Molecular interaction between lacidipine and biological membranes. J Hypertens 1993 ; 11 (suppl 1): S13-9
5. Herbette LG et al. Lercanidipine: short plasma half-life, long duration of action. J Cardiovasc Pharmacol 1997 ; 29 (suppl 1): S19-24
6. Kleinbloesem CH et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987 ; 41 (1): 26-30
7. Meredith PA, Reid JL. Differences between calcium antagonists: duration of action and trough to peak ratio. J Hypertens 1993 : 11 (suppl 1): S21-6
8. Michalewicz L, Messerli FH. Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol 1997 ; 79 (10A): 39-46
9. Micheli D et al. Pharmacology of lacidipine, a vascular-selective calcium antagonist. J Cardiovasc Pharmacol 1991 ; 17 (suppl 4): S1-8
10. 2+-channel by Ro 40-5967. Circ Res 1994 ; 75: 144-8
11. Mulvany MJ, Halpern W. Mechanical properties of vascular smooth muscle cells in situ. Nature 1976 ; 260: 617-9
12. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977 ; 41 (1): 19-26
13. Petrie JR et al. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. J Hypertens 1995 ; 13: 1842-6
14. Pfaffendorf M et al. In vitro effects of nifedipine, nisoldipine, and lacidipine on rat isolated coronary small arteries. J Cardiovasc Pharmacol 1993 ; 21: 496-502
15. Rose M, McMahon, FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990 ; 3: 151-5
16. Satoh H. Parmacology and therapeutic effects of mepirodipine. Cardiovasc Drugs Rev 1991 ; 9 (4): 340-56
17. Tsien RW et al. Molecular biology of calcium channels and structural determinants of key functions. J Cardiovasc Pharmacol 1996 ; 27 (suppl A) : S4-10
18. Videbaek LM et al. Time course of action of amlodipine and felodipine in the rat is most rapid in small arteries. Eur J Pharmacol 1995 ; 274: 109-15
19. Van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens 1993 ; 11 (suppl 1): S3-11